BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Solve ME/CFS Initiative - ECPv6.17.5//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Solve ME/CFS Initiative
X-ORIGINAL-URL:https://solvecfs.org
X-WR-CALDESC:Events for Solve ME/CFS Initiative
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230425T100000
DTEND;TZID=America/New_York:20230425T160000
DTSTAMP:20230301T234226Z
CREATED:20230301T234226Z
LAST-MODIFIED:20230301T234226Z
UID:37888-1682416800-1682438400@solvecfs.org
SUMMARY:FDA Patient-Focused Drug Development Public Meeting for Long Covid
DESCRIPTION:The US Food and Drug Administration (FDA) is hosting a virtual public meeting on Patient-Focused Drug Development for Long Covid on Tuesday\, April 25th\, 2023\, from 10 a.m. to 4:00 p.m. ET.  It will be conducted with live translation in both English and Spanish. \nPatient-Focused Drug Development meetings are important and infrequent opportunities for patients to provide direct input to the FDA\, as well as for the FDA to obtain patient and patient representative input on several aspects related to a disease. ME/CFS was one of the earliest diseases to benefit from the concept of including patients in this process\, approximately a decade ago. \nThis meeting will focus on Long Covid\, how it affects daily life\, symptoms that matter most to patients\, current approaches to treating Long Covid\, and considerations for clinical trial participation. \nSolve M.E. encourages individuals in our community with Long Covid\, family members\, advocates\, caregivers\, and other stakeholders to participate in the live webcast. Register here and find more information on the discussion questions and meeting format\, and find more information on FDA’s website. \nPatients or caregivers who are willing to share their experiences as part of a panel conversation are asked to indicate their willingness as part of registration. They will then be directed to send a short summary of their responses to the discussion questions to PatientFocused@fda.hhs.gov.
URL:https://solvecfs.org/event/fda-patient-focused-drug-development-public-meeting-for-long-covid/
LOCATION:Online
CATEGORIES:Long Covid,Research
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2023/03/Untitled-design-4.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20230427T110000
DTEND;TZID=America/Los_Angeles:20230427T120000
DTSTAMP:20230405T222038Z
CREATED:20230405T221942Z
LAST-MODIFIED:20230405T222038Z
UID:38161-1682593200-1682596800@solvecfs.org
SUMMARY:Effects of Long Covid and ME/CFS on Sleep
DESCRIPTION:Many individuals who have had COVID-19 experience long-term symptoms that have a major impact on their lives. One of the most common symptoms is sleep disturbance. After more than six months from the time of infection\, about 60% of people self-report lingering sleep difficulties\, even if they had a mild course of acute COVID-19. Unrefreshing sleep is also part of the diagnostic criteria for ME/CFS\, along with other overlapping symptoms such as post-exertional malaise (PEM) or “brain fog.” \nTo probe deeper into the topic of sleep\, we are pleased to invite you to a webinar on the Effects of Long Covid and ME/CFS on Sleep\, featuring  SleepScore Lab’s neuroscientist\, Dr. Elie Gottlieb. The presentation will cover a range of topics including: \n\nThe connection between Long Covid\, ME/CFS\, and sleep disturbances.\nThe neurological and cognitive aspects of sleep and how brain changes/disruptions may be bi-directionally associated with Long Covid and ME/CFS.\nUnrefreshing sleep vs. quality sleep and why people with ME/CFS or Long COVID might experience the former.\nThe evidence-based methods to improve sleep and how SleepScore Lab’s improvement program addresses them.\n\n The presentation will be followed by a live Q&A. \nRegister here.
URL:https://solvecfs.org/event/effects-of-long-covid-and-me-cfs-on-sleep/
LOCATION:Online
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2023/04/April-27-Sleepscore-webinar.png
END:VEVENT
END:VCALENDAR